ADMA Biologics Inc

ADMA Healthcare Biotechnology

ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1.98%, EPS grew 21.4%, free cash flow grew 19.7% and total debt rose 140.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

10.68 0.05 −0.47%
Market cap
$2.4B
P/E
14.8×
Fwd P/E
9.5×
Dividend yield
—
F-score
5/9
Altman Z
19.98
Beneish M
−0.17
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
41.90% 43.30% 35.56% 63.17%

+8 more TTM periods

Piotroski F-Score
5 4 5 6
ROA
27.19% 28.13% 26.40% 43.67%
ROIC
29.78% 29.70% 25.69% 23.23%
Return on Tangible Assets
32.55% 32.90% 31.80% 50.39%
Average Days of Receivables
98.49 97.26 113.35 102.85
Free Cash Flow per Share
0.51 0.48 0.12 0.17
Free Cash Flow
116.22 112.55 27.51 40.61
Other line items

Show all line items

Columns are period end dates